

Stephen C Rubin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8946874/stephen-c-rubin-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

226
papers

14,017
citations

62
h-index

114
g-index

238
ext. papers

15,394
ext. citations

5.3
avg, IF

5.56
L-index

#	Paper	IF	Citations
226	Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1203-1209	3.5	6
225	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020 , 159, 79-87	4.9	4
224	Second primary anal and oropharyngeal cancers in cervical cancer survivors. <i>American Journal of Obstetrics and Gynecology</i> , 2019 , 221, 478.e1-478.e6	6.4	6
223	Second primary uterine malignancies after radiation therapy for cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019 , 300, 389-394	2.5	6
222	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1380-1390	2.2	104
221	Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2018 , 38, 395-401	1.3	2
220	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018 , 149, 525-530	4.9	16
219	Basic Principles of Chemotherapy 2018 , 449-469.e2		5
218	Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5580-5580	2.2	
217	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018 , 24, 777-783	12.9	112
216	A preoperative risk score to predict red blood cell transfusion in patients undergoing hysterectomy for ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018 , 219, 598.e1-598.e10	6.4	8
215	Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 598-604	2.7	3
214	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. <i>Clinical Cancer Research</i> , 2017 , 23, 3684-3691	12.9	14
213	Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 779-791	21.7	318
212	National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 1408-1415	3.5	3
211	Blood Loss from Robotic Assisted Hysterectomy. <i>Journal of Gynecologic Surgery</i> , 2017 , 33, 47-50	0.4	
210	Group-based trajectory modeling of fear of disease recurrence among women recently diagnosed with gynecological cancers. <i>Psycho-Oncology</i> , 2017 , 26, 1799-1809	3.9	11

209	AWARE: Randomized study of an EMR-based intervention targeting hereditary cancer (CA) risk awareness in peri-op CA patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e13119-e13119	2.2	
208	Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. <i>Gynecologic Oncology</i> , 2016 , 141, 516-523	4.9	34
207	The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. <i>Gynecologic Oncology</i> , 2016 , 141, 434-439	4.9	8
206	The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 141-8	3.5	17
205	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 738-48	59.2	239
204	Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. <i>Cancer Nursing</i> , 2015 , 38, 375-82	2.6	33
203	Emotion episodes during psychotherapy sessions among women newly diagnosed with gynecological cancers. <i>Psycho-Oncology</i> , 2015 , 24, 1189-96	3.9	4
202	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015 , 137, 386-91	4.9	192
201	CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5522-5522	2.2	2
200	Quality of care for the initial management of stage IB1-IIA2 invasive cervical carcinomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16596-e16596	2.2	
199	The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. <i>Gynecologic Oncology</i> , 2014 , 133, 584-90	4.9	12
198	Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1210-7	2.2	63
197	Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers. <i>General Hospital Psychiatry</i> , 2014 , 36, 81-7	5.6	22
196	Cancer-related concerns among women with a new diagnosis of gynecological cancer: an exploration of age group differences. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 165-71	3.5	9
195	Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1215-21	3.5	7
194	Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease. <i>International Journal of Surgical Pathology</i> , 2014 , 22, 374-7	1.2	3
193	Social-cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers. <i>Gynecologic Oncology</i> , 2013 , 128, 120-127	4.9	45
192	Therapist and patient perceptions of alliance and progress in psychological therapy for women diagnosed with gynecological cancers. <i>Journal of Consulting and Clinical Psychology</i> , 2012 , 80, 800-810	6.5	7

191	A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2012 , 127, 356-61	4.9	15
190	Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. <i>Journal of Gynecologic Oncology</i> , 2012 , 23, 257-64	4	7
189	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 629-41	7.4	94
188	Basic Principles of Chemotherapy 2012 , 515-538.e2		
187	Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. <i>Gynecologic Oncology</i> , 2011 , 120, 108-12	4.9	25
186	Clinical predictors of bevacizumab-associated gastrointestinal perforation. <i>Gynecologic Oncology</i> , 2011 , 120, 464-9	4.9	34
185	A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011 , 121, 264-8	4.9	18
184	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011 , 123, 19-26	4.9	164
183	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2011 , 123, 182-6	4.9	14
182	A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 123, 486-91	4.9	51
181	Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. <i>Cancer Biology and Therapy</i> , 2011 , 12, 367-77	4.6	17
180	Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2011 , 12, 357-66	4.6	8
179	Therapy processes and outcomes of psychological interventions for women diagnosed with gynecological cancers: A test of the generic process model of psychotherapy. <i>Journal of Consulting and Clinical Psychology</i> , 2010 , 78, 236-48	6.5	14
178	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 195-203	4.4	44
177	Epidemiology, staging and clinical characteristics 2010 , 1-23		
176	A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2009 , 115, 215-20	4.9	49
175	Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. <i>Cancer</i> , 2009 , 115, 2891-902	6.4	90
174	Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 773-8	3.5	10

173	Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 83-9	2.2	271
172	Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4151-9	2.2	71
171	Mediators of a coping and communication-enhancing intervention and a supportive counseling intervention among women diagnosed with gynecological cancers. <i>Journal of Consulting and Clinical Psychology</i> , 2008 , 76, 1034-45	6.5	31
170	Long-term trajectories of psychological adaptation among women diagnosed with gynecological cancers. <i>Psychosomatic Medicine</i> , 2008 , 70, 677-87	3.7	26
169	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 533-43	4.4	631
168	Therapy and Prognosis of BRCA-Associated Ovarian Cancer 2008 , 117-127		
167	Coping and communication-enhancing intervention versus supportive counseling for women diagnosed with gynecological cancers. <i>Journal of Consulting and Clinical Psychology</i> , 2007 , 75, 615-628	6.5	61
166	Risk of colorectal cancer in women with a prior diagnosis of gynecologic malignancy. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 291-6	3	7
165	Hereditary Issues In Ovarian Cancer 2007 , 169-193		
164	Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. <i>Gynecologic Oncology</i> , 2006 , 101, 140-2	4.9	62
163	Phase II trial of weekly paclitaxel (80 mg/m ²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 101, 436-40	4.9	176
162	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006 , 20, 307-20	4.6	33
161	A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. <i>Clinical Cancer Research</i> , 2006 , 12, 2517-25	12.9	83
160	Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1311-20	9.7	71
159	Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. <i>American Journal of Epidemiology</i> , 2006 , 164, 775-86	3.8	64
158	Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1894-901	1.9	58
157	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005 , 105, 679-81	2.2	171
156	Ovarian cancer patients' psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem. <i>Health Psychology</i> , 2005 , 24, 143-52	5	84

155	Women with a prior diagnosis of breast cancer are not at an increased risk for subsequent colorectal cancer. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2759-64	0.7	12
154	Epidemiology, staging and clinical characteristics 2005 , 1-37		
153	Secondary surgical cytoreduction for advanced ovarian carcinoma. <i>New England Journal of Medicine</i> , 2004 , 351, 2489-97	59.2	309
152	Prevalence and predictors of psychological distress among women with ovarian cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 919-26	2.2	136
151	RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. <i>Cancer Biology and Therapy</i> , 2004 , 3, 1283-9	4.6	16
150	Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1045-54	2.2	129
149	Delayed hemorrhage after cervical conization unmasking severe factor XI deficiency. <i>Obstetrics and Gynecology</i> , 2004 , 104, 1189-92	4.9	6
148	Management of Intestinal Obstruction in the Terminal Patient and Management of Ascites 2004 , 727-741		2
147	Vaginal cuff recurrence of endometrial cancer treated by laparoscopic-assisted vaginal hysterectomy. <i>Gynecologic Oncology</i> , 2003 , 88, 62-5	4.9	43
146	Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 203-13	59.2	2446
145	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. <i>Biochemical and Biophysical Research Communications</i> , 2003 , 303, 1169-78	3.4	95
144	BRCA1 and BRCA2 Mutations in Ovarian Carcinoma 2003 , 201-208		
143	Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2003 , 9, 264-72	12.9	38
142	TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. <i>Clinical Cancer Research</i> , 2003 , 9, 1517-27	12.9	72
141	Prophylactic oophorectomy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002 , 16, 597-609	4.6	10
140	The clinical course of deep vein thrombosis in patients with gynecologic cancer. <i>Gynecologic Oncology</i> , 2002 , 84, 67-71	4.9	28
139	Prophylactic oophorectomy comes of age. <i>Gynecologic Oncology</i> , 2002 , 85, 395-6	4.9	2
138	Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. <i>American Journal of Pathology</i> , 2002 , 161, 2295-309	5.8	111

137	Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. <i>Clinical Immunology</i> , 2002 , 102, 291-301	9	13
136	Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. <i>Human Gene Therapy</i> , 2002 , 13, 627-39	4.8	58
135	Second-look laparotomy for epithelial ovarian cancer: a reappraisal. <i>Current Oncology Reports</i> , 2001 , 3, 11-8	6.3	13
134	Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. <i>Annals of Surgical Oncology</i> , 2001 , 8, 65-71	3.1	79
133	Survival of BRCA1 negative ovarian cancer patients based on family history. <i>Gynecologic Oncology</i> , 2001 , 83, 109-14	4.9	3
132	Cervical cancer: successes and failures. <i>Ca-A Cancer Journal for Clinicians</i> , 2001 , 51, 89-91	220.7	4
131	Cytoreductive surgery for ovarian cancer. <i>Surgical Clinics of North America</i> , 2001 , 81, 871-83	4	39
130	Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors 2001 , 8, 65		1
129	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. <i>Cancer Gene Therapy</i> , 2000 , 7, 275-83	5.4	57
128	Prolonged remission of recurrent, metastatic placental site trophoblastic tumor after chemotherapy. <i>Gynecologic Oncology</i> , 2000 , 76, 115-7	4.9	20
127	Reply. <i>Gynecologic Oncology</i> , 2000 , 78, 395	4.9	
126	Early ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2000 , 1, 129-37	5.4	5
125	Occult bilateral involvement in stage I epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1999 , 72, 288-91	4.9	65
124	Endometrial carcinoma associated with pregnancy: A report of three cases and review of the literature. <i>Gynecologic Oncology</i> , 1999 , 74, 118-22	4.9	41
123	Intestinal obstruction in advanced ovarian cancer: what does the patient want?. <i>Gynecologic Oncology</i> , 1999 , 75, 311-2	4.9	18
122	Surgical management of ovarian cancer. <i>Journal of Surgical Oncology</i> , 1999 , 17, 173-80		12
121	Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. <i>Obstetrics and Gynecology</i> , 1999 , 93, 21-4	4.9	96
120	Ten-Year Follow-Up of Ovarian Cancer Patients After Second-Look Laparotomy With Negative Findings. <i>Obstetrics and Gynecology</i> , 1999 , 93, 21-24	4.9	65

119	Primary peritoneal carcinoma: a review of the literature. <i>Obstetrical and Gynecological Survey</i> , 1999 , 54, 323-35	2.4	42
118	Endometrial adenocarcinoma with trophoblastic differentiation. <i>Gynecologic Oncology</i> , 1998 , 69, 74-7	4.9	30
117	Clinical characteristics of clear cell carcinoma of the ovary. <i>Gynecologic Oncology</i> , 1998 , 70, 255-8	4.9	133
116	Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. <i>Gynecologic Oncology</i> , 1998 , 70, 432-4	4.9	23
115	BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. <i>American Journal of Obstetrics and Gynecology</i> , 1998 , 178, 670-7	6.4	154
114	Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. <i>Cancer</i> , 1998 , 82, 152-8	6.4	31
113	Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. <i>Molecular Carcinogenesis</i> , 1998 , 23, 243-7	5	27
112	Long-term complications of chemotherapy. <i>Primary Care Update for Ob/Gyns</i> , 1998 , 5, 65-68		0
111	Chemotherapy resistance in ovarian cancer: new molecular perspectives. <i>Obstetrics and Gynecology</i> , 1998 , 91, 783-92	4.9	40
110	BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. <i>Obstetrics and Gynecology</i> , 1998 , 92, 596-600	4.9	55
109	Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 841-5	9.7	105
108	Chemoprevention of hereditary ovarian cancer. <i>New England Journal of Medicine</i> , 1998 , 339, 469-71	59.2	13
107	CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER. <i>Obstetrics and Gynecology</i> , 1998 , 91, 783-792	4.9	24
106	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. <i>Obstetrics and Gynecology</i> , 1998 , 92, 596-600	4.9	24
105	Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2620-4	2.2	118
104	Arterial occlusions as a presenting feature of acute promyelocytic leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998 , 21, 436-7	2.7	12
103	Modern treatment options in epithelial ovarian carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998 , 10, 29-32	2.4	5
102	Advances in cytoreductive surgery of gynecologic cancers. <i>Cancer Treatment and Research</i> , 1998 , 95, 203-17	3.5	0

101	Initial surgical management of advanced epithelial ovarian cancer. <i>Cancer Investigation</i> , 1997 , 15, 270-6	2.1	1
100	Effect of surgical debulking on survival in stage IV ovarian cancer. <i>Gynecologic Oncology</i> , 1997 , 64, 4-8	4.9	84
99	Hereditary ovarian cancer: molecular genetics and clinical implications. <i>Gynecologic Oncology</i> , 1997 , 64, 196-206	4.9	103
98	Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 1997 , 67, 272-6	4.9	5
97	An asymmetric, posterior spacing system for use with mini-ovoids in the treatment of carcinoma of the cervix. <i>International Journal of Gynecological Cancer</i> , 1997 , 7, 350-354	3.5	
96	OncoLink: a cancer information resource for gynecologic oncologists and the public on the Internet. <i>Gynecologic Oncology</i> , 1996 , 60, 8-15	4.9	17
95	Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , 1996 , 62, 55-8	4.9	22
94	Expression of A, B, and H blood group antigens in epithelial ovarian cancer: relationship to tumor grade and patient survival. <i>Gynecologic Oncology</i> , 1996 , 62, 106-12	4.9	22
93	Arterial occlusion complicating treatment of gynecologic cancer: a case series. <i>Gynecologic Oncology</i> , 1996 , 63, 40-6	4.9	17
92	Racial differences in survival from gynecologic cancer. <i>Obstetrics and Gynecology</i> , 1996 , 88, 914-8	4.9	48
91	Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 175, 1260-5	6.4	26
90	Expression and mutational analysis of P53 in stage IB and IIA cervical cancers. <i>American Journal of Obstetrics and Gynecology</i> , 1996 , 175, 1266-71	6.4	15
89	Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. <i>New England Journal of Medicine</i> , 1996 , 335, 1413-6	59.2	360
88	Secondary cytoreduction in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1995 , 18, 1-8	7	13
87	The accuracy of a frozen section diagnosis of borderline ovarian malignancy. <i>Gynecologic Oncology</i> , 1995 , 59, 183-5	4.9	60
86	Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. <i>Gynecologic Oncology</i> , 1995 , 57, 61-5	4.9	123
85	The effect of renal function on serum levels of CA 125. <i>Gynecologic Oncology</i> , 1995 , 58, 375-7	4.9	17
84	Advances in surgery for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1995 , 7, 473-7	4.2	2

83	Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. <i>Cancer</i> , 1995 , 75, 2700-5	6.4	54
82	Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. <i>Cancer</i> , 1994 , 73, 1456-9	6.4	63
81	Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. <i>Cancer</i> , 1994 , 73, 1882-8	6.4	143
80	Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. <i>Cancer</i> , 1993 , 71, 634-7	6.4	58
79	High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies. <i>Gynecologic Oncology</i> , 1993 , 48, 61-7	4.9	20
78	Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. <i>Gynecologic Oncology</i> , 1993 , 48, 185-8	4.9	6
77	The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. <i>Gynecologic Oncology</i> , 1993 , 49, 172-6	4.9	29
76	Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment. <i>Gynecologic Oncology</i> , 1993 , 49, 185-9	4.9	5
75	Impact of age on survival of patients with ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 49, 236-9	4.9	39
74	Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma. <i>Gynecologic Oncology</i> , 1993 , 50, 30-3	4.9	1
73	Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 50, 78-83	4.9	22
72	Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 50, 100-4	4.9	63
71	Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 51, 61-6	4.9	24
70	Secondary cytoreduction--thoughts on the "pro" side. <i>Gynecologic Oncology</i> , 1993 , 51, 127-30	4.9	5
69	Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1993 , 51, 349-54	4.9	8
68	Early invasive carcinoma of the cervix. <i>Gynecologic Oncology</i> , 1993 , 51, 26-32	4.9	47
67	Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. <i>American Journal of Obstetrics and Gynecology</i> , 1993 , 168, 162-9	6.4	108
66	Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1993 , 7, 307-11	2.1	9

65	Intraperitoneal chemotherapy in the management of ovarian cancer. <i>Cancer</i> , 1993 , 71, 1565-70	6.4	33
64	Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. <i>Cancer</i> , 1993 , 71, 1602-12	6.4	18
63	High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. <i>British Journal of Haematology</i> , 1993 , 83, 433-41	4.5	88
62	Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993 , 119, 360-2	4.9	10
61	Phase II trial of zeniplatin (CL 286,558), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1993 , 119, 234-6	4.9	6
60	Surgery for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1992 , 4, 923-9	4.2	1
59	Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. <i>Journal of the National Cancer Institute</i> , 1992 , 84, 1935-6	9.7	31
58	Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1992 , 47, 353-7	4.9	17
57	Endoluminal ultrasound staging of cervical cancer. <i>Gynecologic Oncology</i> , 1992 , 46, 186-90	4.9	10
56	Resection of pulmonary metastases from uterine sarcomas. <i>Gynecologic Oncology</i> , 1992 , 45, 202-5	4.9	105
55	Management of vulvar melanoma. <i>Gynecologic Oncology</i> , 1992 , 45, 254-8	4.9	98
54	Characterization of a human endometrial carcinoma cell line producing intraperitoneal tumor growth in immunodeficient mice. <i>Gynecologic Oncology</i> , 1992 , 45, 273-8	4.9	6
53	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992 , 45, 284-9	4.9	136
52	Management of endometrial adenocarcinoma with cervical involvement. <i>Gynecologic Oncology</i> , 1992 , 45, 294-8	4.9	29
51	Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. <i>Journal of Clinical Oncology</i> , 1992 , 10, 1485-91	2.2	259
50	Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. <i>Journal of Clinical Oncology</i> , 1992 , 10, 1479-84	2.2	71
49	Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. <i>Journal of Clinical Oncology</i> , 1992 , 10, 243-8	2.2	109
48	Surgery for Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992 , 6, 851-865	3.1	8

47	Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 118, 163-5	4.9	11
46	Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 119, 55-7	4.9	50
45	Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 118, 391-4	4.9	2
44	Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 118, 235-7	4.9	4
43	Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991 , 117, 89-90	4.9	27
42	Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991 , 164, 558-63	6.4	19
41	Extended-field radiation therapy in early-stage cervical carcinoma: survival and complications. <i>Gynecologic Oncology</i> , 1991 , 43, 51-4	4.9	40
40	Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. <i>Gynecologic Oncology</i> , 1991 , 43, 159-63	4.9	14
39	Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy. <i>Gynecologic Oncology</i> , 1991 , 40, 17-20	4.9	12
38	Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. <i>Gynecologic Oncology</i> , 1991 , 41, 101-6	4.9	60
37	Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma. <i>Gynecologic Oncology</i> , 1991 , 41, 217-9	4.9	5
36	Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 1991 , 42, 137-41	4.9	106
35	Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. <i>Gynecologic Oncology</i> , 1991 , 42, 156-60	4.9	36
34	Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. <i>Journal of Clinical Oncology</i> , 1991 , 9, 1801-5	2.2	155
33	Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 1991 , 9, 978-82	2.2	29
32	Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. <i>Journal of Clinical Oncology</i> , 1991 , 9, 204-10	2.2	41
31	Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. <i>Journal of Clinical Oncology</i> , 1991 , 9, 389-93	2.2	677
30	Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. <i>Journal of Urology</i> , 1991 , 146, 1104-7; discussion 1107-8	2.5	18

29	Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.. <i>Journal of Consulting and Clinical Psychology</i> , 1990 , 58, 153-157	6.5	64
28	Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. <i>Journal of Clinical Oncology</i> , 1990 , 8, 146-50	2.2	65
27	Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions. <i>Journal of Histochemistry and Cytochemistry</i> , 1990 , 38, 1677-81	3.4	25
26	Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance. <i>American Journal of Obstetrics and Gynecology</i> , 1990 , 163, 69-73	6.4	32
25	Aggressive chemosurgical debulking in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1990 , 38, 358-63	4.9	27
24	Treatment of endometrial stromal tumors. <i>Gynecologic Oncology</i> , 1990 , 36, 60-5	4.9	143
23	Paget disease of the vulva. <i>Gynecologic Oncology</i> , 1990 , 39, 374-7	4.9	97
22	Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. <i>Journal of Clinical Oncology</i> , 1989 , 7, 1327-32	2.2	78
21	Palliative surgery for intestinal obstruction in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 1989 , 34, 16-9	4.9	98
20	Intestinal surgery in gynecologic oncology. <i>Gynecologic Oncology</i> , 1989 , 34, 30-3	4.9	24
19	Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer. <i>Gynecologic Oncology</i> , 1989 , 34, 353-6	4.9	6
18	Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1989 , 34, 365-71	4.9	105
17	A longitudinal study of antigen expression in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1989 , 34, 389-94	4.9	15
16	Long-term access to the peritoneal cavity in ovarian cancer patients. <i>Gynecologic Oncology</i> , 1989 , 33, 46-8	4.9	21
15	Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1989 , 160, 667-71	6.4	92
14	Second-look surgery in ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1988 , 8, 75-91	7	29
13	Ovarian cancer. Diagnosis and surgical treatment. <i>AORN Journal</i> , 1988 , 47, 1427-31, 1434, 1436-7	0.6	
12	Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. <i>American Journal of Obstetrics and Gynecology</i> , 1988 , 159, 1094-8	6.4	75

11	Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer. <i>Journal of Clinical Oncology</i> , 1988 , 6, 158-62	2.2	12
10	A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. <i>Journal of Clinical Oncology</i> , 1988 , 6, 689-95	2.2	51
9	Postmenopausal bleeding: etiology, evaluation, and management. <i>Medical Clinics of North America</i> , 1987 , 71, 59-69	7	7
8	Radical hysterectomy for recurrent cervical cancer following radiation therapy. <i>Gynecologic Oncology</i> , 1987 , 27, 316-24	4.9	30
7	Well-differentiated adenocarcinoma of endometrium with simple karyotypic changes: a case report. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 25, 21-6		22
6	Endometrial curettage at the time of cervical conization. <i>Obstetrics and Gynecology</i> , 1986 , 67, 663-4	4.9	2
5	Tumor Antigens in Ovarian Malignancy. <i>Clinical Obstetrics and Gynecology</i> , 1986 , 29, 693-704	1.7	10
4	Lymph node nomenclature in gynecologic oncology. <i>Gynecologic Oncology</i> , 1986 , 23, 222-6	4.9	18
3	Squamous carcinoma of the vagina: treatment, complications, and long-term follow-up. <i>Gynecologic Oncology</i> , 1985 , 20, 346-53	4.9	77
2	Para-aortic nodal metastases in early cervical carcinoma: long-term survival following extended-field radiotherapy. <i>Gynecologic Oncology</i> , 1984 , 18, 213-7	4.9	35
1	Serum fucose as a monitor for recurrent malignancy. <i>Journal of Surgical Oncology</i> , 1978 , 10, 39-44	2.8	9